Comparison of 89Zr Panitumumab and (18)F-Fluorodeoxyglucose to Identify Head and Neck Squamous Cell Carcinoma

NCT05183048 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

RECRUITING

Status

14

Enrollment

OTHER

Sponsor class

Conditions

Head and Neck Squamous Cell Carcinoma

Interventions

DRUG: [89Zr]Panitumumab Tracer

Sponsor

University of Alabama at Birmingham